Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer

ClinicalTrials.gov ID: NCT07408089

Public ClinicalTrials.gov record NCT07408089. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 5, 2026, 3:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Multicenter, First-in-Human, Phase 1 Study of BBI-940 in Advanced or Metastatic Breast Cancer: Kinesin Oral Molecular Degrader for Oncology (KOMODO-1)

Study identification

NCT ID: NCT07408089
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Boundless Bio, Inc.; Industry
Enrollment: 96 participants

Conditions and interventions

Conditions

Interventions

BBI-940 Drug
Fulvestrant Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 24, 2026
Primary completion: Feb 27, 2029
Completion: May 30, 2029
Last update posted: Apr 12, 2026

2026 – 2029

United States locations

U.S. sites: 8
U.S. states: 4
U.S. cities: 7

Facility	City	State	ZIP	Site status
The START Center for Cancer Research	Los Angeles	California	90025	Recruiting
The START Center for Cancer Research	Lake Success	New York	11042	Recruiting
NEXT Oncology	Austin	Texas	78758	Recruiting
University of Texas Southwestern Medical Center	Dallas	Texas	75390	Recruiting
NEXT Oncology	Houston	Texas	77054	Recruiting
NEXT Oncology	San Antonio	Texas	78229	Recruiting
The START Center for Cancer Care	San Antonio	Texas	78229	Recruiting
NEXT Oncology	Fairfax	Virginia	22031	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07408089, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 12, 2026 · Synced May 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07408089 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →